IDH1 and acute myeloid leukemia: Ivosidenib was selected for downstream experiments since this drug performed well compared with other tested compounds (Fig. 4a), is well tolerated in patients and is already FDA approved for medically refractory IDH1-mutant acute myeloid leukemia and IDH1-mutant cholangiocarcinoma49–51.